Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
AbbVie presented late-breaking Phase 2 data at SGO 2026 showing that Mirvetuximab Soravtansine PSOC treatment combined with carboplatin achieved a 62.7% response rate in FRα-high patients, offering a new hope for platinum-sensitive recurrence.
TECNIS PureSee IOL clinical data took center stage at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, as Johnson & Johnson [Read More…]
Johnson & Johnson MedTech has announced the European launch of its latest pulsed field ablation innovation, VARIPULSE Pro, designed to enhance procedural efficiency and precision in treating cardiac arrhythmias.
Amgen has announced successful topline results from its Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA® for Thyroid Eye Disease, offering a new, convenient delivery method.
AstraZeneca announces positive results from the EMERALD-2 Phase III trial, proving that the Imfinzi and Imjudo liver cancer treatment significantly delays disease recurrence in patients following surgery or ablation.
New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.
A new subgroup analysis from the Phase 3 VESALIUS-CV trial reveals that Amgen’s Repatha reduces the risk of first major cardiovascular events by 31% in high-risk patients without known atherosclerosis.
Johnson & Johnson has announced breakthrough one-year data for ICOTYDE (icotrokinra), demonstrating that the once-daily oral peptide maintains high rates of skin clearance and a favorable safety profile in patients with plaque psoriasis.
